SCHEMBL5488536

SCHEMBL5488536

CC(=O)Nc1ccc(C2(c3ccc(NC(C)=O)cc3)C(=O)Nc3c(C)cc(Cl)cc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
CNR1 P21554 1/20 0.43
HTT P42858 1/20 0.43
GPR35 Q9HC97 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
ALDH1A1 P00352 3/20 0.40
MAPT P10636 1/20 0.40
LRRK2 Q5S007 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
IDO1 P14902 1/20 0.38
NQO2 P16083 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA9 Q16790 2/20 0.37
CA2 P00918 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ESR1 P03372 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483441 0.85 SMN1; SMN2 (0.52) SMN1; SMN2HTTALDH1A1MAPTKDM4E
SCHEMBL5486000 0.82 CNR1 (0.63) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5485863 0.81 HTT (0.67) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5478939 0.79 SMN1; SMN2 (0.56) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5486789 0.74 SMN1; SMN2 (0.56) SMN1; SMN2HTTALDH1A1MAPTLRRK2
SCHEMBL5482126 0.74 SMN1; SMN2 (0.56) SMN1; SMN2HTTALDH1A1MAPTLRRK2
SCHEMBL5479179 0.74 SMN1; SMN2 (0.53) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5482300 0.73 SMN1; SMN2 (0.52) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5478145 0.72 SMN1; SMN2 (0.60) SMN1; SMN2HTTALDH1A1MAPTTDP1
SCHEMBL5486626 0.72 GPR55 (0.68) SMN1; SMN2CNR1HTTGPR35GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 SMN1; SMN2 234/4885CNR1 973/4885HTT 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.